Trans-activation of heparanase promoter by ETS transcription factors

W. C. Lu, Y. N. Liu, B. B. Kang, J. H. Chen

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

The remodeling of extracellular matrix (ECM) is an important process required for cancer cells to turn into invasive and metastatic cancer cells. To dissolve the protein components of ECM, matrix metalloproteinases are some of the essential enzymes. Another ECM remodeling enzyme is the heparanase (Hpa) that digests the heparin sulfate component of the matrix. In metastatic cancer cells the Hpa gene is upregulated. To investigate the mechanism of why Hpa was upregulated in metastatic cancer cells, the regulatory sequence of heparanase gene was isolated and its function analysed in metastatic breast cancer cells. We found there are four ETS transcription factor binding sites. Two of them flanking the transcription initiation of the Hpa gene are nonfunctional, whereas two others are highly functional and responded to exogenously added ETS transcription factors. Mutation of these two ETS binding sites abolished the transcriptional activation of Hpa promoter by ETS transcription factors. Among four transcription factors tested (ETS1, ETS2, PEA3, and ER81), ETS1 and ETS2 are more potent in transactivating the human Hpa gene. Furthermore, dominant-negative ETS transcription factors failed to transactivate Hpa promoter and could abrogate the function of wild-type transcription factor in transactivation activity of ETS transcription factors on the Hpa promoter. These results suggest that ETS transcription factors play an important role in tumor invasion and metastasis by modulating the remodeling of ECM.

Original languageEnglish
Pages (from-to)919-923
Number of pages5
JournalOncogene
Volume22
Issue number6
DOIs
Publication statusPublished - Feb 13 2003
Externally publishedYes

Fingerprint

Transcription Factors
Extracellular Matrix
Neoplasms
Transcriptional Activation
Genes
Binding Sites
heparanase
Extracellular Matrix Proteins
Enzymes
Matrix Metalloproteinases
Sulfates
Heparin
Breast Neoplasms
Neoplasm Metastasis
Mutation

Keywords

  • ETS
  • Heparanase promoter
  • Tumor metastasis

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Trans-activation of heparanase promoter by ETS transcription factors. / Lu, W. C.; Liu, Y. N.; Kang, B. B.; Chen, J. H.

In: Oncogene, Vol. 22, No. 6, 13.02.2003, p. 919-923.

Research output: Contribution to journalArticle

Lu, W. C. ; Liu, Y. N. ; Kang, B. B. ; Chen, J. H. / Trans-activation of heparanase promoter by ETS transcription factors. In: Oncogene. 2003 ; Vol. 22, No. 6. pp. 919-923.
@article{1ae4e23815414e91846fcbbd0a58c010,
title = "Trans-activation of heparanase promoter by ETS transcription factors",
abstract = "The remodeling of extracellular matrix (ECM) is an important process required for cancer cells to turn into invasive and metastatic cancer cells. To dissolve the protein components of ECM, matrix metalloproteinases are some of the essential enzymes. Another ECM remodeling enzyme is the heparanase (Hpa) that digests the heparin sulfate component of the matrix. In metastatic cancer cells the Hpa gene is upregulated. To investigate the mechanism of why Hpa was upregulated in metastatic cancer cells, the regulatory sequence of heparanase gene was isolated and its function analysed in metastatic breast cancer cells. We found there are four ETS transcription factor binding sites. Two of them flanking the transcription initiation of the Hpa gene are nonfunctional, whereas two others are highly functional and responded to exogenously added ETS transcription factors. Mutation of these two ETS binding sites abolished the transcriptional activation of Hpa promoter by ETS transcription factors. Among four transcription factors tested (ETS1, ETS2, PEA3, and ER81), ETS1 and ETS2 are more potent in transactivating the human Hpa gene. Furthermore, dominant-negative ETS transcription factors failed to transactivate Hpa promoter and could abrogate the function of wild-type transcription factor in transactivation activity of ETS transcription factors on the Hpa promoter. These results suggest that ETS transcription factors play an important role in tumor invasion and metastasis by modulating the remodeling of ECM.",
keywords = "ETS, Heparanase promoter, Tumor metastasis",
author = "Lu, {W. C.} and Liu, {Y. N.} and Kang, {B. B.} and Chen, {J. H.}",
year = "2003",
month = "2",
day = "13",
doi = "10.1038/sj.onc.1206201",
language = "English",
volume = "22",
pages = "919--923",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Trans-activation of heparanase promoter by ETS transcription factors

AU - Lu, W. C.

AU - Liu, Y. N.

AU - Kang, B. B.

AU - Chen, J. H.

PY - 2003/2/13

Y1 - 2003/2/13

N2 - The remodeling of extracellular matrix (ECM) is an important process required for cancer cells to turn into invasive and metastatic cancer cells. To dissolve the protein components of ECM, matrix metalloproteinases are some of the essential enzymes. Another ECM remodeling enzyme is the heparanase (Hpa) that digests the heparin sulfate component of the matrix. In metastatic cancer cells the Hpa gene is upregulated. To investigate the mechanism of why Hpa was upregulated in metastatic cancer cells, the regulatory sequence of heparanase gene was isolated and its function analysed in metastatic breast cancer cells. We found there are four ETS transcription factor binding sites. Two of them flanking the transcription initiation of the Hpa gene are nonfunctional, whereas two others are highly functional and responded to exogenously added ETS transcription factors. Mutation of these two ETS binding sites abolished the transcriptional activation of Hpa promoter by ETS transcription factors. Among four transcription factors tested (ETS1, ETS2, PEA3, and ER81), ETS1 and ETS2 are more potent in transactivating the human Hpa gene. Furthermore, dominant-negative ETS transcription factors failed to transactivate Hpa promoter and could abrogate the function of wild-type transcription factor in transactivation activity of ETS transcription factors on the Hpa promoter. These results suggest that ETS transcription factors play an important role in tumor invasion and metastasis by modulating the remodeling of ECM.

AB - The remodeling of extracellular matrix (ECM) is an important process required for cancer cells to turn into invasive and metastatic cancer cells. To dissolve the protein components of ECM, matrix metalloproteinases are some of the essential enzymes. Another ECM remodeling enzyme is the heparanase (Hpa) that digests the heparin sulfate component of the matrix. In metastatic cancer cells the Hpa gene is upregulated. To investigate the mechanism of why Hpa was upregulated in metastatic cancer cells, the regulatory sequence of heparanase gene was isolated and its function analysed in metastatic breast cancer cells. We found there are four ETS transcription factor binding sites. Two of them flanking the transcription initiation of the Hpa gene are nonfunctional, whereas two others are highly functional and responded to exogenously added ETS transcription factors. Mutation of these two ETS binding sites abolished the transcriptional activation of Hpa promoter by ETS transcription factors. Among four transcription factors tested (ETS1, ETS2, PEA3, and ER81), ETS1 and ETS2 are more potent in transactivating the human Hpa gene. Furthermore, dominant-negative ETS transcription factors failed to transactivate Hpa promoter and could abrogate the function of wild-type transcription factor in transactivation activity of ETS transcription factors on the Hpa promoter. These results suggest that ETS transcription factors play an important role in tumor invasion and metastasis by modulating the remodeling of ECM.

KW - ETS

KW - Heparanase promoter

KW - Tumor metastasis

UR - http://www.scopus.com/inward/record.url?scp=0037434721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037434721&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1206201

DO - 10.1038/sj.onc.1206201

M3 - Article

C2 - 12584571

AN - SCOPUS:0037434721

VL - 22

SP - 919

EP - 923

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 6

ER -